Dronedarone (Multaq) (Dronedarone (Dronedaron)) and Ziprasidone: interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
Ziprasidone combined with another established QT-prolonging drug can increase the risk of a serious rhythm disturbance. CYP3A4 inhibition may increase ziprasidone exposure.
Clinical significance and safety
Dronedarone (Multaq) and Ziprasidone: Ziprasidone combined with another established QT-prolonging drug can increase the risk of a serious rhythm disturbance. CYP3A4 inhibition may increase ziprasidone exposure. The ziprasidone label advises avoiding other established QT-prolonging drugs. Heart disease, a slow pulse and low potassium or magnesium can increase concern. A clinician determines whether ECG or electrolyte checks are needed. Fainting or new irregular palpitations require urgent assessment. Changes in exposure can affect tolerability or treatment response. The prescriber must check the exact inhibitor, formulation, dose and timing against the cited product information; doses should not be adjusted without that review.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.